Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
A lack of profits can lead to trouble, but StockStory helps you identify the businesses that stand a chance of making it through. That said, here are three unprofitable companiesthat don’t make the cut and some better opportunities instead.
Stratasys (SSYS)
Trailing 12-Month GAAP Operating Margin: -15.8%
Born from the Founder’s idea of making a toy frog with a glue gun, Stratasys (NASDAQ: SSYS) offers 3D printers and related materials, software, and services to many industries.
Why Does SSYS Worry Us?
- Sales tumbled by 6.2% annually over the last two years, showing market trends are working against it during this cycle
- Historical operating margin losses point to an inefficient cost structure
- Cash-burning tendencies make us wonder if it can sustainably generate shareholder value
Stratasys is trading at $8.42 per share, or 62.8x forward P/E. Check out our free in-depth research report to learn more about why SSYS doesn’t pass our bar.
Methode Electronics (MEI)
Trailing 12-Month GAAP Operating Margin: 1.1%
Founded in 1946, Methode Electronics (NYSE: MEI) is a global supplier of custom-engineered solutions for Original Equipment Manufacturers (OEMs).
Why Do We Steer Clear of MEI?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 1.3% annually over the last five years
- Sales were less profitable over the last five years as its earnings per share fell by 18.6% annually, worse than its revenue declines
- Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned
At $14.92 per share, Methode Electronics trades at 40.6x forward P/E. To fully understand why you should be careful with MEI, check out our full research report (it’s free).
Avantor (AVTR)
Trailing 12-Month GAAP Operating Margin: -4.5%
With roots dating back to 1904 and embedded in virtually every stage of scientific research and production, Avantor (NYSE: AVTR) provides mission-critical products, materials, and services to customers in biopharma, healthcare, education, and advanced technology industries.
Why Are We Out on AVTR?
- Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
- Sales are projected to be flat over the next 12 months and imply weak demand
- Earnings per share fell by 4.5% annually over the last five years while its revenue was flat, showing each sale was less profitable
Avantor’s stock price of $9.64 implies a valuation ratio of 11.6x forward P/E. Dive into our free research report to see why there are better opportunities than AVTR.
Stocks We Like More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
